CN102065841A - 利用脂质体肉毒杆菌毒素对膀胱功能障碍的治疗 - Google Patents

利用脂质体肉毒杆菌毒素对膀胱功能障碍的治疗 Download PDF

Info

Publication number
CN102065841A
CN102065841A CN2009801204554A CN200980120455A CN102065841A CN 102065841 A CN102065841 A CN 102065841A CN 2009801204554 A CN2009801204554 A CN 2009801204554A CN 200980120455 A CN200980120455 A CN 200980120455A CN 102065841 A CN102065841 A CN 102065841A
Authority
CN
China
Prior art keywords
bont
bladder
liposomes
formulation
instillation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801204554A
Other languages
English (en)
Chinese (zh)
Inventor
迈克尔·B·钱塞勒
乔纳森·H·考夫曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lipella Pharmaceuticals Inc
Original Assignee
Lipella Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipella Pharmaceuticals Inc filed Critical Lipella Pharmaceuticals Inc
Publication of CN102065841A publication Critical patent/CN102065841A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2009801204554A 2008-04-04 2009-04-03 利用脂质体肉毒杆菌毒素对膀胱功能障碍的治疗 Pending CN102065841A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4253608P 2008-04-04 2008-04-04
US61/042,536 2008-04-04
US11026608P 2008-10-31 2008-10-31
US61/110,266 2008-10-31
PCT/US2009/039489 WO2009139984A2 (en) 2008-04-04 2009-04-03 Method of treatment for bladder dysfunction

Publications (1)

Publication Number Publication Date
CN102065841A true CN102065841A (zh) 2011-05-18

Family

ID=41319235

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801204554A Pending CN102065841A (zh) 2008-04-04 2009-04-03 利用脂质体肉毒杆菌毒素对膀胱功能障碍的治疗

Country Status (10)

Country Link
US (1) US20120093920A1 (enExample)
EP (2) EP2273976A2 (enExample)
JP (2) JP5538359B2 (enExample)
KR (1) KR20100131471A (enExample)
CN (1) CN102065841A (enExample)
AU (1) AU2009246834B2 (enExample)
BR (1) BRPI0911098A2 (enExample)
CA (1) CA2720523C (enExample)
MX (1) MX2010010635A (enExample)
WO (1) WO2009139984A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117883383A (zh) * 2023-12-26 2024-04-16 中国康复研究中心 一种作为A型肉毒素载体的TiO2纳米粒子及制备方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
ES2660901T3 (es) 2012-04-13 2018-03-26 Lubrizol Advanced Materials, Inc. Compuestos que inhiben la exocitosis neuronal (II)
RU2657591C2 (ru) 2012-08-31 2018-06-14 ТАРИС Биомедикал ЛЛК Способ лечения рака мочевого пузыря оксалиплатином, соответствующее устройство его доставки, способ и устройство его введения
KR102383496B1 (ko) 2012-08-31 2022-04-08 타리스 바이오메디컬 엘엘씨 젬시타빈을 포함하는 전립선 질환의 치료를 위한 약물 전달 시스템과 방법
CA2927356C (en) 2013-10-22 2022-08-23 Lipella Pharmaceuticals Inc. Delivery of agents using metastable liposomes
US20160045623A1 (en) 2015-04-03 2016-02-18 Lipella Pharmaceuticals, Inc. Systems and Methods to Image Intercellular and Intercompartmental Defects with Magnetic Resonance Imaging (MRI)
WO2019023388A1 (en) 2017-07-25 2019-01-31 Taris Biomedical Llc METHODS OF TREATING TUMOR METASTASIS
WO2019046311A1 (en) 2017-08-28 2019-03-07 Revance Therapeutics, Inc. TRANSMUCOSAL COMPOSITIONS OF BOTULINUM TOXIN, KITS AND METHODS FOR TREATING BLADDER DISORDERS
PE20210041A1 (es) 2017-11-08 2021-01-08 Taris Biomedical Llc Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina
KR102398743B1 (ko) * 2020-09-03 2022-05-16 충남대학교병원 초음파유도 마이크로버블을 포함하는 배뇨장애 치료제 조성물
TWI760996B (zh) * 2020-12-25 2022-04-11 姜秉均 含有疏水性物質的奈米組成物及其製備方法與用途
US12272439B1 (en) 2024-05-06 2025-04-08 Immunitybio, Inc. Distributed ledger for medicament administration tracking

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3693209B2 (ja) * 1996-04-11 2005-09-07 三菱化学株式会社 閉鎖小胞の製造方法
WO2003015698A2 (en) 2001-08-13 2003-02-27 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
WO2003101483A1 (en) * 2002-05-31 2003-12-11 Solux Corporation Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
AU2003259246A1 (en) 2002-07-29 2004-02-16 Rajiv Doshi Methods for the use of neurotoxin in the treatment of urologic disorders
AU2003287526A1 (en) * 2002-11-06 2004-06-03 Protein-stabilized liposomal formulations of pharmaceutical agents
EP1933813A4 (en) * 2005-10-11 2013-02-27 Univ Pittsburgh SPHINGOMYELIN LIPOSOME FOR THE TREATMENT OF HYPERACTIVE BLADDER DISORDER

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117883383A (zh) * 2023-12-26 2024-04-16 中国康复研究中心 一种作为A型肉毒素载体的TiO2纳米粒子及制备方法

Also Published As

Publication number Publication date
MX2010010635A (es) 2010-12-17
AU2009246834B2 (en) 2012-12-06
CA2720523C (en) 2013-12-17
US20120093920A1 (en) 2012-04-19
CA2720523A1 (en) 2009-11-19
JP5538359B2 (ja) 2014-07-02
KR20100131471A (ko) 2010-12-15
BRPI0911098A2 (pt) 2015-10-06
EP2599476A1 (en) 2013-06-05
AU2009246834A1 (en) 2009-11-19
JP2014062125A (ja) 2014-04-10
EP2273976A2 (en) 2011-01-19
WO2009139984A2 (en) 2009-11-19
WO2009139984A3 (en) 2010-03-04
JP2011516497A (ja) 2011-05-26

Similar Documents

Publication Publication Date Title
AU2009246834B2 (en) Treatment of bladder dysfunction using liposomal botulinum toxin
Chancellor et al. Treatment of interstitial cystitis
Fraser et al. Intravesical liposome administration—a novel treatment for hyperactive bladder in the rat
JP2003519666A (ja) 膵臓障害の処置方法
Yu et al. Sequential drug release of co-assembled supramolecular hydrogel as synergistic therapy against Staphylococcus aureus endophthalmitis
Xia et al. Comprehensive dry eye therapy: overcoming ocular surface barrier and combating inflammation, oxidation, and mitochondrial damage
US20120301540A1 (en) Method of treatment for bladder dysfunction
Lv et al. Chitosan as a promising materials for the construction of nanocarriers for diabetic retinopathy: an updated review
Zhang et al. Inhalation of taraxasterol loaded mixed micelles for the treatment of idiopathic pulmonary fibrosis
Zhang et al. An injectable thermosensitive hyaluronic acid/pluronic F-127 hydrogel for deep penetration and combination therapy of frozen shoulder
He et al. Targeted-lung delivery of bardoxolone methyl using PECAM-1 antibody-conjugated nanostructure lipid carriers for the treatment of lung inflammation
RU2527679C2 (ru) Терапевтическое средство для лечения заболевания нижних мочевых путей и средство для улучшения симптома нижних мочевых путей
Crane et al. Current therapeutic strategies in clinical urology
Gupta et al. Understanding the routes of administration
CN105342984A (zh) 一种用于治疗急性胰腺炎的可注射温敏凝胶制剂
CN115942945A (zh) 含源自副干酪乳杆菌的细胞外囊泡的预防或治疗眼病的组合物
US8283323B2 (en) Withanolide compounds as inhibitors of fibrosis and identification of molecular targets for anti-fibrotic drug development
Bao et al. Thermo-responsive in situ gel of fluticasone propionate nanosuspension modified with carboxymethyl chitosan for enhanced blepharitis therapy
US20240115503A1 (en) Intravesical delivery of hydrophilic therapeutic agents using liposomes
CN120420276B (zh) 一种治疗干眼症的纳米胶束药物及其制备方法
CN100364610C (zh) 提高蚓激酶口服吸收生物利用度的方法
KR102398743B1 (ko) 초음파유도 마이크로버블을 포함하는 배뇨장애 치료제 조성물
Asif et al. Interstitial Cystitis-Critical Assessment of Current Treatment and Opportunities for Nanodelivery
Liao et al. A Dual-Targeted Liposomal Nanosystem for Co-Delivery of Estrogen Receptor β Antagonist and Disulfiram for the Non-Hormonal Treatment of Endometriosis
RU2694226C1 (ru) Фармацевтическая композиция для лечения заболеваний глаз, сопровождающихся окислительным стрессом, и способ ее применения

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20110518

RJ01 Rejection of invention patent application after publication